top of page
< Back

Infliximab


Mechanism of action:

Infliximab is a chimeric monoclonal antibody (mouse/human chimeric antibody) that specifically targets tumor necrosis factor-α (TNF-α). It binds both soluble and membrane-bound TNF-α, preventing TNF-α from interacting with its receptors TNFR1 and TNFR2. This suppresses the activation of multiple downstream inflammatory signaling pathways and reduces TNF-α-mediated inflammatory signal transduction.

Reference(s):

1. Present DH et al. (1999). Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 


2. Sands BE et al. (2004). Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 


3. Klotz U et al. (2007). Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet.

bottom of page